AUSTIN, Texas, and HAMILTON, Ontario – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that Senior Management will participate in four upcoming healthcare investor conferences.
Oppenheimer Private Company Showcase: The Next Wave: presentation at 2:35 pm PT on Tuesday, October 18th and available for investor meetings
Bank of America Healthcare Life Sciences Private Company Conference: available for in-person investor meetings on Thursday, October 20th
Wells Fargo Private Biotech Symposium: available for virtual investor meetings on Wednesday, November 2nd
Stifel 2022 Healthcare Conference: presentation on Wednesday, November 16th at 9:10 am ET and available for investor meetings
AUSTIN, Texas, and HAMILTON, Ontario, Sep. 6, 2022 – Triumvira Immunologics (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, today announced that it will present interim clinical data from its ongoing TACTIC-2 clinical trial (NCT04727151) for TAC01-HER2 in a poster presentation at the upcoming European Society for Medical Oncology (ESMO) Congress, being held Sept. 9-13, 2022 in Paris, France. TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2).
Details of presentation:
Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors Presenter: Benjamin L. Schlechter, M.D., GI-Medical Oncology at Dana-Farber Cancer Institute Abstract #: 778TiP Date: Monday, Sept. 12, 2022 Time: 11:00 a.m. – 12:00 p.m. CEST Location: Paris Expo Porte de Versailles, Hall 4
Dr. Jonathan Bramson to be presenting at 3:20 p.m. CT on June 1.
At the IOBDLI Forum, Triumvira Scientific Founder and Acting Chief Scientific Officer, Dr. Jonathan Bramson, will provide an overview of the company’s T Cell-Antigen Coupler (TAC) technology, as well as updates on Triumvira’s lead drug, CD19-TAC01, which is targeted to enter clinical development in H1 2019 for the treatment of patients with CD19 positive B-cell malignancies. Dr. Bramson will be presenting at 3:20 p.m. CT on June 1.
Triumvira President and Chief Executive Officer, Dr. Paul Lammers available for private meetings June 4-5
At BIO International, Triumvira Immunologics President and Chief Executive Officer, Dr. Paul Lammers will be available for private meetings during the day on June 4-5 to discuss potential collaboration and licensing opportunities for the Company’s novel immuno-oncology platform T Cell-Antigen Coupler (TAC).
Triumvira will be presenting at ISCT 2018 – May 2-5, 2018 at the Palais des Congrès de Montréal in Montréal, QC, Canada
ISCT is the premier cell therapy translation society focused on pre-clinical, clinical and translational aspects of developing cell therapy products. As such, ISCT helps academic, government and biotech/pharma sectors transform research into practice and product.
ISCT 2018 is expected to draw over 1,600 delegates globally. The Annual Meeting will serve as the prime opportunity for you to network with experts within the global cell therapy arena.
Triumvira will be presenting at the Bloom Burton & Co. Healthcare Investor Conference on May 2 and 3, 2018 at the Sheraton Centre Toronto Hotel in Toronto, ON., Canada
This year, BBHIC will host approximately 60 of Canada’s premier publicly-traded and venture-backed private companies together with the most promising pre-venture companies in the healthcare industry. Our agenda includes company presentations, keynote sessions and panel discussions by industry leaders.